-

Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen

TOKUSHIMA, Japan--(BUSINESS WIRE)--Following to the previous information on Jan. 30th. in 2024, we are excited to share our latest development status.

FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen have been done on March 8th, 2024.

The Phase I/II study of DFP-10917 with VTX in the above AML patients shall be started at Wake Forest and the other hospitals soon after FDA approval.

The interim analysis of the Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US is undergoing for the reason there are patients with a long-term survival may effect on OS analysis.

The invention with the combination of DFP-14927 with VTX in AML was granted in Japan, US, and Taiwan.

Please take notice of our own innovative approach for miserable cancer patients and contact with us.

Contacts

Inquires
Scott Frank
Vice President for Business Development
Delta-Fly Pharma, Inc.
Head office: Tokushima 771-0117, Japan
Phone: +81-3-6231-1278
E-mail: sfrank1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/

Industry:

Delta-Fly Pharma, Inc.

TOKYO:4598
Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)

Contacts

Inquires
Scott Frank
Vice President for Business Development
Delta-Fly Pharma, Inc.
Head office: Tokushima 771-0117, Japan
Phone: +81-3-6231-1278
E-mail: sfrank1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/

More News From Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax

TOKUSHIMA, Japan--(BUSINESS WIRE)--Following to the previous information on Dec. 9th. in 2024, we are excited to share our latest development status. Regarding the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) in second-line therapy (NCT06382168), the Data Management Committee (DMC) has approved the tolerability of all six patients in the Phase I (dose finding) portion of the Phase I/II study, and we are moving to the P...

Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax

TOKUSHIMA, Japan--(BUSINESS WIRE)--Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status. We are pleased to announce that the data review committee (DMC) has approved the tolerability of the first three patients enrolled in the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) (NCT06382168) conducted at five US clinical sites for patients with acute myeloid leukemia (AML) who have failed/relapsed after standa...

Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729

TOKUSHIMA, Japan--(BUSINESS WIRE)--We are excited to share our latest development status. We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved. In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed aga...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.